Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa. In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension. Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Insmed Incorporated

Jefferies analyst Kelly Shi maintained a Buy rating on Insmed today and set a price target of $230.00. According to TipRanks, Shi is a 4-star analy...

Jefferies Sticks to Their Buy Rating for Insmed (INSM)

Insmed ( ($INSM) ) has provided an announcement. On November 18, 2025, Insmed announced that the European Commission approved BRINSUPRI (brensocati...

Insmed’s BRINSUPRI Approved by European Commission

RBC Capital analyst Leonid Timashev reiterated a Buy rating on Insmed yesterday and set a price target of $215.00. The company’s shares closed yest...

Insmed (INSM) Gets a Buy from RBC Capital

In a report released yesterday, Maxwell Skor from Morgan Stanley maintained a Hold rating on Insmed, with a price target of $158.00. The company’s ...

Market Cap	$35.04B	P/E Ratio	N/A
52W High	$208.00	52W Low	$60.40
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-12.8%	52W Position	93.7%
Overall Score	65	Value Score	40
Quality Score	--	Technical Score	91

EPS Current Est	$-6.21	EPS Next Est	$-3.65
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	INSM	$198.76	-0.44%	2.63M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	INSM	$198.76	-0.4%	2.63M
3
4
5
6

INSM

INSM

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Insmed Incorporated Data in Excel

Get Insmed Incorporated Data in Excel